DNY59 Tyra Biosciences ( NASDAQ: TYRA ) stock plunged 17% in morning trading Friday after the company reported interim Phase 1/2 data from a study for its drug candidate TYRA-300 in the treatment of a certain type of metastatic urothelial cancer, or mUC. The.
Back to Health Page
